Literature DB >> 10950770

Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption.

E Papasavvas1, G M Ortiz, R Gross, J Sun, E C Moore, J J Heymann, M Moonis, J K Sandberg, L A Drohan, B Gallagher, J Shull, D F Nixon, J R Kostman, L J Montaner.   

Abstract

Immunologic and virologic outcomes of treatment interruption were compared for 5 chronically human immunodeficiency virus (HIV)-infected persons who have maintained antiretroviral therapy-mediated virus suppression, as compared with 5 untreated controls. After a median interruption of 55 days of therapy accompanied by rebound of virus, reinitiated therapy in 4 of 5 subjects resulted in suppression of 98.86% of plasma virus load by 21-33 days and no significant decrease in CD4 T cell percentage from baseline. Increased T helper responses against HIV-1 p24 antigen (P=. 014) and interferon-gamma-secreting CD8 T cell responses against HIV-1 Env (P=.004) were present during interruption of therapy and after reinitiation of treatment. The remaining subject whose treatment was interrupted did not resume treatment and continued to have a low virus load (<1080 HIV-1 RNA copies/mL) and persistent antiviral cell-mediated responses. In summary, cellular immunity against autologous HIV-1 has the potential to be acutely augmented in association with temporary treatment interruption in chronically infected persons.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10950770     DOI: 10.1086/315748

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Authors:  G M Ortiz; M Wellons; J Brancato; H T Vo; R L Zinn; D E Clarkson; K Van Loon; S Bonhoeffer; G D Miralles; D Montefiori; J A Bartlett; D F Nixon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

2.  Immune Reconstitution Strategies in HIV.

Authors:  Matthew R. Leibowitz; Ronald T. Mitsuyasu
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

Review 3.  Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.

Authors:  Ume L Abbas; John W Mellors
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

4.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Authors:  Annette Oxenius; David A Price; Huldrych F Günthard; Sara J Dawson; Catherine Fagard; Luc Perrin; Marek Fischer; Rainer Weber; Montserrat Plana; Felipe García; Bernard Hirschel; Angela McLean; Rodney E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

5.  Retention of functional DC-NK cross-talk following up to 18 weeks therapy interruptions in chronically suppressed HIV type 1+ subjects.

Authors:  Emmanouil Papasavvas; Jihed Chehimi; Livio Azzoni; Maxwell Pistilli; Brian Thiel; Agnieszka Mackiewicz; Shenoa Creer; Karam Mounzer; Jay R Kostman; Luis J Montaner
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08-18       Impact factor: 2.205

6.  Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.

Authors:  Koen K A Van Rompay; Raman P Singh; Walid Heneine; Jeffrey A Johnson; David C Montefiori; Norbert Bischofberger; Marta L Marthas
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Short communication: CD8(+) T cell polyfunctionality profiles in progressive and nonprogressive pediatric HIV type 1 infection.

Authors:  Christina F Thobakgale; Hendrik Streeck; Nompumelelo Mkhwanazi; Zenele Mncube; Lungile Maphumulo; Fundisiwe Chonco; Andrew Prendergast; Gareth Tudor-Williams; Bruce D Walker; Philip J R Goulder; Marcus Altfeld; Thumbi Ndung'u
Journal:  AIDS Res Hum Retroviruses       Date:  2011-03-21       Impact factor: 2.205

Review 8.  Structured treatment interruption in patients infected with HIV: a new approach to therapy.

Authors:  Roy M Gulick
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.

Authors:  Annette Oxenius; Angela R McLean; Marek Fischer; David A Price; Sarah J Dawson; Roland Hafner; Christine Schneider; Helen Joller; Bernard Hirschel; Rodney E Phillips; Rainer Weber; Huldrych F Günthard
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women.

Authors:  Emmanouil Papasavvas; Lea F Surrey; Deborah K Glencross; Livio Azzoni; Jocelin Joseph; Tanvier Omar; Michael D Feldman; Anna-Lise Williamson; Maureen Siminya; Avril Swarts; Xiangfan Yin; Qin Liu; Cynthia Firnhaber; Luis J Montaner
Journal:  Oncoimmunology       Date:  2016-01-19       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.